Mckesson outlines fiscal 2027 adjusted EPS of $45.60-$46.40 while closing $2.25B Precision Medicine Group deal

• "Second quarter revenues increased 8% with growth across all segments, while adjusted earnings per diluted share increased 18% year-over-year." (CEO & Chairman Brian Tyler)

• "As a result of our strong

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.